WuXi AppTec(02359) Peptide solid phase synthesis reactor capacity will be increased to 130,000 liters. It is expected that the annual TIDES revenue will reach close to 16 billion yuan.

In the face of the continuous market demand for metabolic disease drugs such as GLP-1, WuXi AppTec (603259.SH, 02359), which has deep accumulation in this field, has once again pressed the "accelerate button" for expansion. At the latest performance communication meeting, the company announced that it will further increase its investment in the peptide and oligonucleotide (TIDES) business: not only planning to significantly increase the total volume of solid-phase synthesis reaction vessels to 130,000 liters, but also preparing for the construction of three new workshops. With the dual driving force of huge production capacity and strong orders, the company expects the TIDES business to usher in a new round of high-speed growth in 2026, with annual revenue aiming for over RMB 15 billion. The increase in the scale of solid-phase synthesis reaction vessels to 130,000 liters this time is another key measure for WuXi AppTec to address the "exponential growth capacity demand for GLP-1 drugs." Previously, the company had already completed construction of over 100,000 liters of capacity by the end of the third quarter of 2025. The surge in new production capacity in the next phase will further strengthen its production barriers and delivery certainty in the global peptide CDMO field, providing solid guarantees for taking on more late-stage clinical and commercial orders. The company's expectation of nearly RMB 16 billion in annual revenue from the TIDES business is based on its solid order base and continued release of production capacity. Data shows that the revenue from this business exceeded RMB 10 billion for the first time in 2025. As of the end of the first quarter, the number of customers and molecules served in the TIDES business increased by 28% and 59% respectively year-on-year, with ample growth momentum. The continuous expansion of production capacity will directly support the business in moving towards a new billion-dollar milestone. The rapid growth of WuXi AppTec's TIDES business has greatly benefited from the global research and development frenzy for GLP-1. Currently, the company is providing research and production support for 24 GLP-1 drugs, 15 of which have entered phase II and III clinical trials. With its forward-looking production capacity layout and strong technical platform, WuXi AppTec is able to continuously capture the outsourcing demand for complex molecular research and further consolidate its core position in the global pharmaceutical innovation supply chain.